Inicio>>Signaling Pathways>> Others>>Bimosiamose (TBC 1269)

Bimosiamose (TBC 1269) (Synonyms: TBC 1269)

Catalog No.GC33908

La bimosiamosa (TBC 1269) (TBC-1269) es un antagonista de pan-selectina no oligosacÁrido con IC50 de 88 μM, 20 μM y 86 μM para E-selectina, P-selectina y L-selectina, respectivamente .

Products are for research use only. Not for human use. We do not sell to patients.

Bimosiamose (TBC 1269) Chemical Structure

Cas No.: 187269-40-5

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
317,00 $
Disponible
1mg
56,00 $
Disponible
5mg
167,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Bimosiamose is a pan-selectin antagonist, inhibits E-, P-, and L-selectin with IC50s of 88 μM, 20 μM, and 86 μM, respectively, and can be used in the research of inflammatory disease.

Bimosiamose is a pan-selectin antagonist, inhibits E-, P-, and L-selectin with IC50s of 88 μM, 20 μM, and 86 μM, respectively, and can be used in the research of inflammatory disease[1].

Bimosiamose (25 mg/kg, i.v.) significantly improves the survival in rats subjected to severe hepatic ischemia and reperfusion. Bimosiamose also causes lower ALT enzyme levels and decreases neutrophil infiltration[1].

[1]. Palma-Vargas JM, et al. Small-molecule selectin inhibitor protects against liver inflammatory response after ischemia and reperfusion. J Am Coll Surg. 1997 Oct;185(4):365-72.

Reseñas

Review for Bimosiamose (TBC 1269)

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Bimosiamose (TBC 1269)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.